See other bills
under the
same topic
                                                       PRINTER'S NO. 275

THE GENERAL ASSEMBLY OF PENNSYLVANIA


SENATE BILL

No. 238 Session of 2007


        INTRODUCED BY KASUNIC, COSTA, BOSCOLA, FONTANA, LAVALLE,
           RAFFERTY, TARTAGLIONE, MUSTO, ORIE, KITCHEN AND RHOADES,
           MARCH 8, 2007

        REFERRED TO JUDICIARY, MARCH 8, 2007

                                     AN ACT

     1  Amending the act of April 14, 1972 (P.L.233, No.64), entitled
     2     "An act relating to the manufacture, sale and possession of
     3     controlled substances, other drugs, devices and cosmetics;
     4     conferring powers on the courts and the secretary and
     5     Department of Health, and a newly created Pennsylvania Drug,
     6     Device and Cosmetic Board; establishing schedules of
     7     controlled substances; providing penalties; requiring
     8     registration of persons engaged in the drug trade and for the
     9     revocation or suspension of certain licenses and
    10     registrations; and repealing an act," further providing for
    11     schedules of controlled substances.

    12     The General Assembly of the Commonwealth of Pennsylvania
    13  hereby enacts as follows:
    14     Section 1.  Section 4(1) of the act of April 14, 1972
    15  (P.L.233, No.64), known as The Controlled Substance, Drug,
    16  Device and Cosmetic Act, amended November 24, 1999 (P.L.894,
    17  No.55), is amended to read:
    18     Section 4.  Schedules of Controlled Substances.--The
    19  following schedules include the controlled substances listed or
    20  to be listed by whatever official name, common or usual name,
    21  chemical name, or trade name designated.
    22     (1)  Schedule I--In determining that a substance comes within

     1  this schedule, the secretary shall find: a high potential for
     2  abuse, no currently accepted medical use in the United States,
     3  and a lack of accepted safety for use under medical supervision.
     4  The following controlled substances are included in this
     5  schedule:
     6     (i)  Any of the following opiates, including their isomers,
     7  esters, ethers, salts, and salts of isomers, esters, and ethers,
     8  unless specifically excepted, whenever the existence of such
     9  isomers, esters, ethers and salts is possible within the
    10  specific chemical designation:
    11      1.  Acetylmethadol.
    12      2.  Allylprodine.
    13      3.  Alphacetylmethadol.
    14      4.  Alphameprodine.
    15      5.  Alphamethadol.
    16      6.  Benzethidine.
    17      7.  Betacetylmethadol.
    18      8.  Betameprodine.
    19      9.  Betamethadol.
    20     10.  Betaprodine.
    21     11.  Clonitazene.
    22     12.  Dextromoramide.
    23     13.  Dextrorphan (except its methylether).
    24     14.  Diampromide.
    25     15.  Diethylthiambutene.
    26     16.  Dimenoxadol.
    27     17.  Dimepheptanol.
    28     18.  Dimethylthiambutene.
    29     19.  Dioxaphetyl butyrate.
    30     20.  Dipipanone.
    20070S0238B0275                  - 2 -     

     1     21.  Ethylmethylthiambutene.
     2     22.  Etonitazene.
     3     23.  Etoxeridine.
     4     24.  Furethidine.
     5     25.  Hydroxypethidine.
     6     26.  Ketobemidone.
     7     27.  Levomoramide.
     8     28.  Levophenacylmorphan.
     9     29.  Morpheridine.
    10     30.  Noracymethadol.
    11     31.  Norlevorphanol.
    12     32.  Normethadone.
    13     33.  Norpipanone.
    14     34.  Phenadoxone.
    15     35.  Phenampromide.
    16     36.  Phenomorphan.
    17     37.  Phenoperidine.
    18     38.  Piritramide.
    19     39.  Proheptazine.
    20     40.  Properidine.
    21     41.  Racemoramide.
    22     42.  Trimeperidine.
    23     (ii)  Any of the following opium derivatives, their salts,
    24  isomers and salts of isomers, unless specifically excepted,
    25  whenever the existence of such salts, isomers and salts of
    26  isomers is possible within the specific chemical designation:
    27     1.  Acetorphine.
    28     2.  Acetyldihydrocodeine.
    29     3.  Benzylmorphine.
    30     4.  Codeine methylbromide.
    20070S0238B0275                  - 3 -     

     1     5.  Codeine-N-Oxide.
     2     6.  Cyprenorphine.
     3     7.  Desomorphine.
     4     8.  Dihydromorphine.
     5     9.  Etorphine.
     6    10.  Heroin.
     7    11.  Hydromorphinol.
     8    12.  Methyldesorphine.
     9    13.  Methylhydromorphine.
    10    14.  Morphine methylbromide.
    11    15.  Morphine methylsulfonate.
    12    16.  Morphine-N-Oxide.
    13    17.  Myrophine.
    14    18.  Nicocodeine.
    15    19.  Nicomorphine.
    16    20.  Normorphine.
    17    21.  Pholcodine.
    18    22.  Thebacon.
    19     (iii)  Any material, compound, mixture, or preparation which
    20  contains any quantity of the following hallucinogenic
    21  substances, their salts, isomers, and salts of isomers, unless
    22  specifically excepted, whenever the existence of such salts,
    23  isomers, and salts of isomers is possible within the specific
    24  chemical designation:
    25     1.  3,4-methylenedioxy amphetamine.
    26     2.  5-methoxy-3,4-methylenedioxy amphetamine.
    27     3.  3,4,5-trimethoxy amphetamine.
    28     4.  Bufotenine.
    29     5.  Diethyltryptamine.
    30     6.  Dimethyltryptamine.
    20070S0238B0275                  - 4 -     

     1     7.  4-methyl-2,5-dimethoxyamphetamine.
     2     8.  Ibogaine.
     3     9.  Lysergic acid diethylamide.
     4    10.  Mescaline.
     5    11.  Peyote.
     6    12.  N-ethyl-3-piperidyl benzilate.
     7    13.  N-methyl-3-piperidyl benzilate.
     8    14.  Psilocybin.
     9    15.  Psilocyn.
    10    16.  Tetrahydrocannabinols.
    11     (iv)  Marihuana.
    12     (v)  Any material, compound, mixture or preparation which
    13  contains any quantity of the following substances, including the
    14  salts, isomers and salts of isomers:
    15     1.  Methaqualone.
    16     (vi)  Gamma hydroxybutyric acid, any salt, hydroxybutyric
    17  compound, derivative or preparation of gamma hydroxybutyric
    18  acid, including any isomers, esters and ethers and salts of
    19  isomers, esters and ethers of gamma hydroxybutyric acid, except
    20  gamma-butyrolactone (GBL), whenever the existence of such
    21  isomers, esters and salts is possible within the specific
    22  chemical designation. For purposes of security requirements
    23  imposed by law or regulation upon registered distributors and
    24  registered manufacturers, this substance when manufactured,
    25  distributed or possessed in accordance with an exemption
    26  approved under section 505(i) of the Federal Food, Drug, and
    27  Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.) shall,
    28  notwithstanding any other provision of this act, be classified
    29  as a controlled substance in Schedule III of this section.
    30     (vii)  Oxycontin, including any isomers, esters and ethers
    20070S0238B0275                  - 5 -     

     1  and salts of isomers, esters and ethers of oxycontin, whenever
     2  the existence of such isomers, esters and salts is possible
     3  within the specific designation, except when used by a person
     4  diagnosed with a disease or disorder that causes chronic pain.
     5     Section 2.  This act shall take effect in 60 days.

















    L19L35SFL/20070S0238B0275        - 6 -